<DOC>
	<DOCNO>NCT00461812</DOCNO>
	<brief_summary>The research hypothesis propose study ask question , Asmanex® demonstrate comparable anti-inflammatory therapeutic efficacy combination product , Advair® control mild persistent asthma ? The purpose demonstrate anti-inflammatory protection afford monotherapy inhale steroid ( Asmanex® ) comparable combination therapy Advair® 100/50 , measure standard methodology ( methacholine bronchoprovocation ) subject mild persistent asthma .</brief_summary>
	<brief_title>A Comparison Mometasone Advair Patients With Milder Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>subject 18 65 year age &gt; 2 year history asthma FEV1 &gt; 80 % subject currently use Advair® . severe asthma current smoker pregnant breastfeed woman chronic significant illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>